# C_2015357EN.01001601.xml

| 29.10.2015 | EN | Official Journal of the European Union | C 357/16 |
| --- | --- | --- | --- |

29.10.2015

EN

Official Journal of the European Union

C 357/16

---

Prior notification of a concentration

(Case M.7787 — Panasonic Healthcare/Bayer’s Diabetes Care Business)

(Text with EEA relevance)

(2015/C 357/06)

| 1. | On 22 October 2015, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Panasonic Healthcare Holding Co., Ltd (‘PHCHD’, Japan), holding company of Panasonic Healthcare (‘PHC’), indirectly controlled by private equity funds managed by affiliates of KKR & Co. LP (‘KKR’, United States), acquires within the meaning of Article 3(1)(b) of the Merger Regulation, sole control of Bayer AG’s diabetes care business (‘BDC’, Germany) by way of purchase of shares and assets. |
| --- | --- |

1.

On 22 October 2015, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Panasonic Healthcare Holding Co., Ltd (‘PHCHD’, Japan), holding company of Panasonic Healthcare (‘PHC’), indirectly controlled by private equity funds managed by affiliates of KKR & Co. LP (‘KKR’, United States), acquires within the meaning of Article 3(1)(b) of the Merger Regulation, sole control of Bayer AG’s diabetes care business (‘BDC’, Germany) by way of purchase of shares and assets.

1

| 2. | The business activities of the undertakings concerned are:
  —   for KKR: global alternative asset manager and provider of financial advisory services,
  —   for PHCHD: holding company,
  —   for PHC: development, manufacture and sale of in vitro diagnostic devices and life science devices and services,
  —   for BDC: distribution of blood glucose monitoring systems. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   for KKR: global alternative asset manager and provider of financial advisory services,

for KKR

—   for PHCHD: holding company,

for PHCHD

—   for PHC: development, manufacture and sale of in vitro diagnostic devices and life science devices and services,

for PHC

—   for BDC: distribution of blood glucose monitoring systems.

for BDC

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.7787 — Panasonic Healthcare/Bayer’s Diabetes Care Business, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.7787 — Panasonic Healthcare/Bayer’s Diabetes Care Business, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---